Twin Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.85M Sell
27,595
-396
-1% -$55.5K 0.5% 45
2025
Q4
$3.44M Sell
27,991
-346
-1% -$42K 0.43% 56
2025
Q3
$3.15M Sell
28,337
-4,987
-15% -$567K 0.4% 63
2025
Q2
$3.69M Buy
33,324
+538
+2% +$57.3K 0.39% 67
2025
Q1
$3.67M Buy
32,786
+2,392
+8% +$247K 0.43% 63
2024
Q4
$2.81M Buy
30,394
+606
+2% +$54.6K 0.31% 85
2024
Q3
$2.5M Sell
29,788
-467
-2% -$35.6K 0.28% 98
2024
Q2
$2.08M Buy
30,255
+734
+2% +$49K 0.24% 112
2024
Q1
$2.16M Sell
29,521
-2,204
-7% -$169K 0.27% 110
2023
Q4
$2.57M Buy
31,725
+6,093
+24% +$474K 0.34% 86
2023
Q3
$1.92M Sell
25,632
-1,386
-5% -$107K 0.28% 107
2023
Q2
$2.08M Sell
27,018
-1,123
-4% -$89.6K 0.27% 109
2023
Q1
$2.33M Buy
+28,141
New +$2.33M 0.32% 99
2022
Q1
Sell
-9,980
Closed -$725K 282
2021
Q4
$725K Sell
9,980
-730
-7% -$50.3K 0.07% 228
2021
Q3
$748K Buy
10,710
+159
+2% +$11.2K 0.08% 233
2021
Q2
$727K Sell
10,551
-199
-2% -$13.3K 0.07% 240
2021
Q1
$695K Sell
10,750
-1,110
-9% -$71.6K 0.07% 240
2020
Q4
$691K Sell
11,860
-849
-7% -$51.2K 0.06% 235
2020
Q3
$803K Sell
12,709
-202
-2% -$14K 0.07% 226
2020
Q2
$993K Sell
12,911
-173
-1% -$13.3K 0.1% 201
2020
Q1
$978K Buy
13,084
+4,450
+52% +$307K 0.11% 191
2019
Q4
$561K Sell
8,634
-200
-2% -$13K 0.05% 248
2019
Q3
$560K Sell
8,834
-480
-5% -$31.4K 0.04% 244
2019
Q2
$629K Sell
9,314
-28,026
-75% -$1.84M 0.04% 239
2019
Q1
$2.43M Sell
37,340
-100
-0.3% -$6.65K 0.12% 204
2018
Q4
$2.34M Sell
37,440
-5,515
-13% -$385K 0.13% 190
2018
Q3
$3.32M Buy
42,955
+4,705
+12% +$355K 0.15% 177
2018
Q2
$2.71M Sell
38,250
-42,990
-53% -$3.04M 0.14% 194
2018
Q1
$6.13M Sell
81,240
-16,480
-17% -$1.31M 0.32% 108
2017
Q4
$7M Buy
97,720
+890
+0.9% +$67.6K 0.34% 96
2017
Q3
$7.84M Buy
96,830
+24,470
+34% +$1.87M 0.41% 74
2017
Q2
$5.12M Buy
72,360
+3,450
+5% +$230K 0.3% 106
2017
Q1
$4.68M Sell
68,910
-51,480
-43% -$3.62M 0.29% 108
2016
Q4
$8.62M Buy
120,390
+6,330
+6% +$470K 0.55% 47
2016
Q3
$9.02M Sell
114,060
-5,240
-4% -$426K 0.6% 40
2016
Q2
$9.95M Buy
119,300
+410
+0.3% +$36.4K 0.75% 31
2016
Q1
$10.9M Buy
118,890
+4,610
+4% +$416K 0.85% 30
2015
Q4
$11.6M Buy
114,280
+11,590
+11% +$1.21M 0.95% 27
2015
Q3
$10.1M Buy
102,690
+1,790
+2% +$199K 0.96% 24
2015
Q2
$11.8M Sell
100,900
-5,700
-5% -$623K 1.06% 17
2015
Q1
$10.5M Buy
106,600
+10,960
+11% +$1.11M 0.92% 22
2014
Q4
$9.02M Buy
95,640
+6,340
+7% +$656K 0.86% 23
2014
Q3
$9.51M Buy
89,300
+5,580
+7% +$546K 0.96% 18
2014
Q2
$6.94M Buy
83,720
+320
+0.4% +$24.9K 0.7% 32
2014
Q1
$5.91M Buy
83,400
+38,340
+85% +$3.01M 0.62% 36
2013
Q4
$3.38M Buy
45,060
+13,180
+41% +$918K 0.36% 87
2013
Q3
$2M Buy
31,880
+5,650
+22% +$338K 0.21% 143
2013
Q2
$1.34M Buy
+26,230
New +$1.37M 0.14% 184

Other funds holding GILD

Twin Capital Management's GILD Position: Q1 2026 in Review

Twin Capital Management reduced its Gilead Sciences (GILD) stake by 1.4% in Q1 2026, selling an estimated $55.5K and leaving 27,595 shares worth $3.85M. The position accounts for 0.5% of the portfolio, ranked #45.

Twin Capital Management first reported a position in GILD in Q2 2013 and has held it in 48 quarters since. The position peaked at $11.8M in Q2 2015. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Twin Capital Management held 27,595 shares of Gilead Sciences worth $3.85M as of Q1 2026.
  • Twin Capital Management sold 396 Gilead Sciences shares in Q1 2026, an estimated $55.5K.
  • Gilead Sciences made up 0.5% of Twin Capital Management's portfolio in Q1 2026, its #45 holding.
  • Twin Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 48 quarters since.
  • Twin Capital Management's Gilead Sciences position peaked at $11.8M in Q2 2015.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.